Maxcyte, Inc. SEC filings MXCT

Maxcyte, Inc. has 336 filings in SEC EDGAR's recent list, going back to Apr 14, 2004. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 14, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
DEFA14A Additional proxy material Apr 29, 2026 —
DEF 14A Proxy statement Apr 29, 2026 Jun 17, 2026
DEFA14A Additional proxy material May 29, 2025 —
DEF 14A Proxy statement Apr 28, 2025 Jun 18, 2025
PRE 14A Preliminary proxy statement Apr 15, 2025 Jun 18, 2025
DEF 14A Proxy statement Apr 26, 2024 Jun 11, 2024
DEF 14A Proxy statement Apr 28, 2023 Jun 22, 2023
DEF 14A Proxy statement May 26, 2022 Jun 29, 2022
DEF 14A Proxy statement Oct 1, 2021 Oct 29, 2021

Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Services-Commercial Physical & Biological Research (SIC 8731)
Listed as
MXCT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Rockville, MD
SEC filer status
, Emerging growth company
SEC CIK
1287098
Former names
MAXCYTE INC (until Sep 18, 2008)

Other Services-Commercial Physical & Biological Research companies

All 17 Services-Commercial Physical & Biological Research companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.